Takeda to Advance FIN-524 Development Program in Ulcerative Colitis

 Takeda to Advance FIN-524 Development Program in Ulcerative Colitis

Takeda to Advance FIN-524 Development Program in Ulcerative Colitis

Shots:

  • Takeda will lead the development of FIN-524/TAK-524 to treat UC prior to the start of its clinical program & will leverage its expertise in IBD throughout the development process
  • Finch plans to provide ongoing technical support through the P-I trial of FIN-524/TAK-524 in the same indication. The companies will continue to advance the program for CD
  • In 2017, Takeda & Finch collaborated to develop TAK-524 for IBD under which Finch has received $10M upfront, $4M in milestone, and is eligible to receive an additional ~ $176M as additional milestones along with royalties on WW net sales of the therapy. Finch was primarily responsible for early-stage development activities through P-II study

Click here to­ read full press release/ article | Ref: Finch Therapeutics | Image: Businesswire

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post